drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-14. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
=== Mortality risk === A 2012 study found a significantly lower ischemic heart disease mortality (-29%) and overall cancer incidence (-18%) in vegetarians in comparison to nonvegetarians. A 2017 review found a lower mortality (−25%) from ischemic heart disease.
In April 2024, Panera launched a major menu overhaul marketed as the "New Era at Panera," which the company described as the most significant menu transformation in its history. The update involved discontinuing categories such as flatbread pizzas and grain bowls to refocus on core offerings like soups, salads, and sandwiches. The change introduced over 20 new or enhanced items with larger portions and lower price points in a strategic effort to improve value and increase customer traffic. On February 14, 2025, Ken Rosenthal, the founder of St. Louis Bread Company, died at age 81 due to complications from Alzheimer's disease. In March 2025, the company named Paul Carbone its new CEO. In July 2025, it was announced that the company was continuing a move begun in 2024 to a "par-baked" model for its restaurants, closing down existing dough-making facilities, and laying off employees. This model has restaurants receive partially-baked ("Par-baked") frozen bread which is finished in the store instead of freshly baked every day. The company has also been reportedly rolling back their "clean food guidelines" which previously advocated for stances against antibiotics and hormones, and for animal welfare.
=== Major neuroendocrine axes === Oxytocin and vasopressin (also called anti-diuretic hormone), the two neurohypophysial hormones of the posterior pituitary gland (the neurohypophysis), are secreted from the nerve endings of magnocellular neurosecretory cells into the systemic circulation. The cell bodies of the oxytocin and vasopressin neurons are in the paraventricular nucleus and supraoptic nucleus of the hypothalamus, respectively, and the electrical activity of these neurons is regulated by afferent synaptic inputs from other brain regions. By contrast, the hormones of the anterior pituitary gland (the adenohypophysis) are secreted from endocrine cells that, in mammals, are not directly innervated, yet the secretion of these hormones (adrenocorticotrophic hormone, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, prolactin, and growth hormone) remains under the control of the hypothalamus. The hypothalamus controls the anterior pituitary gland via releasing factors and release-inhibiting factors; these are substances released by hypothalamic neurons into blood vessels at the base of the brain, at the median eminence. These vessels, the hypothalamo-hypophysial portal vessels, carry the hypothalamic factors to the anterior pituitary, where they bind to specific receptors on the surface of the hormone-producing cells. For example, the secretion of growth hormone is controlled by two neuroendocrine systems: the growth hormone-releasing hormone (GHRH) neurons and the somatostatin neurons, which stimulate and inhibit GH secretion, respectively.
== Anabolic agents == Anabolic agents, or Anabolic Androgenic Steroids (AAS), are any of a group of synthetic or natural steroid hormones that builds muscle by mimicking or increasing male-producing characteristics, such as testosterones. Anabolic agents are abused by athletes in training to increase the size and strength of their muscles. However, the muscle growth only occurs when combined with rigorous physical training. Examples of anabolic agents are boldenone, clenbuterol, dehydrocholormethyl-testosterone (DHEA), nandrolone, stanozolol, testosterone, methasterone, androstenedione, norandrostenedione, methandienone, etiocholanolone, and trenbolone. Exceptions to the ban are phenylephrine and pseudoephedrine.
Sources: en.wikipedia.org
Fifth generation In the 1990s, the fifth generation of silicone-gel breast prosthesis contained a semi-solid silicone-gel with a viscosity that reduced the occurrence of filler leakage and the occurrence of the filler migration throughout the woman's body of any silicone-filler that leaked from the implant-pocket. The plastic surgery studies Experience with Anatomical, Soft Cohesive Silicone-gel Prosthesis in Cosmetic and Reconstructive Breast Implant Surgery (2004) and Cohesive Silicone-gel Breast Implants in Aesthetic and Reconstructive Breast Surgery (2005) reported lower incidence-rates of capsular contracture and lower incidence-rates of shell rupture, and rates of medical safety and technical efficacy greater than the rates of safety and efficacy of early-generation prosthetic breasts.
== Live Well Foundation philanthropy == In 2022, GNC Live Well Foundation partnered with Filmrise and director Nate Boyer to support his first film "MVP", while also holding a fundraising campaign for Boyer's nonprofit organization, Merging Vets & Players. The GNC Live Well Foundation is also the national sponsor for the film throughout the 2022-23 NFL season. With a stated mission to encourage and assist people in living well, the company has donated over $1 million to MVP in December 2020. This nonprofit organization was founded by Jay Glazer and Nate Boyer in 2015 in order to address the challenges that military veterans and retired athletes face when transitioning to civilian life. Starting from December 2020, the company has made a donation that exceeds $1 million to Merging Vets and Players (MVP). Jay Glazer, a Fox Sports NFL Insider, and Nate Boyer, a former green beret and Seattle Seahawk, established MVP in 2015. The goal of the non-profit organization is to tackle the difficulties that combat veterans and former professional athletes encounter as they transition to civilian life after leaving their respective professions. While the foundation aims to improve public health through its various initiatives, its association with GNC raises questions about its independence and the authenticity of its objectives.
=== Small animal imaging === A miniature animal PET has been constructed that is small enough for a fully conscious rat to be scanned. This RatCAP (rat conscious animal PET) allows animals to be scanned without the confounding effects of anesthesia. PET scanners designed specifically for imaging rodents, often referred to as microPET, as well as scanners for small primates, are marketed for academic and pharmaceutical research. The scanners are based on microminiature scintillators and amplified avalanche photodiodes (APDs) through a system that uses single-chip silicon photomultipliers. In 2018 the UC Davis School of Veterinary Medicine became the first veterinary center to employ a small clinical PET scanner as a scanner for clinical (rather than research) animal diagnosis. Because of cost as well as the marginal utility of detecting cancer metastases in companion animals (the primary use of this modality), veterinary PET scanning is expected to be rarely available in the immediate future.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.